I happen to agree with the concept of pre-treating with immune-ablative therapeutics. That said, I'm starting to believe results from trials like these wildly vary depending on the mouse models. The more I talk to onc researchers about preclinical testing, the deeper understanding I get about how truly terrible the animal models are for cancer.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC